Bhojani-Lynch Tahera, Deckers Anne, Ohanes Ohan, Poupard Kevin, Maffert Pauline
The Laser and Light Clinic, Loughborough, UK.
Centre Médical Esthétique Eureka, Dalhem, Belgium.
Clin Cosmet Investig Dermatol. 2021 Nov 16;14:1685-1695. doi: 10.2147/CCID.S329415. eCollection 2021.
Monitoring the effectiveness, safety and emerging uses of hyaluronic acid (HA) fillers in their wide range of indications requires a holistic approach.
To propose an observational study design aiming to gather real-world evidence (RWE) and continuously evaluate the performance and safety of marketed devices in routine practice.
A prospective, observational registry was initiated at six European sites. Investigators enrolled any subject receiving at least one injection with a target study device (TEOSYAL Deep Lines [HA] and/or Global Action [HA]). They followed their routine practice regarding injection technique, volume, and subject follow-up. Effectiveness was evaluated at 3 months using the global aesthetic improvement scale (GAIS). Safety was assessed based on common treatment reactions (CTR) and adverse events (AE).
High quantity of RWE was collected following the initiation of this registry. In the first 158 subjects enrolled, 1220 injections were performed in more than 25 indications, including 679 with the target devices and 271 with devices of the same filler line. The primary objective was achieved, with 93.9% of treatments providing improvement at Month 3 according to the PI and subject. Post-injection CTR were mild to moderate and short-lived, and there was no clinically significant AE. More than 76% of treatments still provided some visible effect at month 12.
Based on RWE, HA and HA are effective and safe in their respective indications mostly distributed in the midface, perioral region, and lower face. Observational registries are a valuable asset in the context of post-market clinical follow-up.
监测透明质酸(HA)填充剂在其广泛适应症中的有效性、安全性及新出现的用途需要一种整体的方法。
提出一项观察性研究设计,旨在收集真实世界证据(RWE),并在常规实践中持续评估上市产品的性能和安全性。
在欧洲的六个地点启动了一项前瞻性观察性登记研究。研究人员纳入了任何接受至少一次目标研究器械(TEOSYAL Deep Lines [HA]和/或Global Action [HA])注射的受试者。他们遵循关于注射技术、注射量和受试者随访的常规做法。在3个月时使用整体美学改善量表(GAIS)评估有效性。基于常见治疗反应(CTR)和不良事件(AE)评估安全性。
该登记研究启动后收集了大量的RWE。在最初纳入的158名受试者中,针对超过25种适应症进行了1220次注射,其中包括使用目标器械进行的679次注射和使用同一填充剂系列器械进行的271次注射。主要目标得以实现,根据研究者和受试者的评估,93.9%的治疗在第3个月时实现了改善。注射后的CTR为轻度至中度且持续时间短,并且没有具有临床意义的AE。超过76%的治疗在第12个月时仍有一些可见效果。
基于RWE,HA填充剂在其各自主要分布于中面部、口周区域和下面部的适应症中是有效且安全的。观察性登记研究在上市后临床随访中是一项宝贵的资产。